250 related articles for article (PubMed ID: 28500307)
21. Recurrent
Matsuo H; Yoshida K; Fukumura K; Nakatani K; Noguchi Y; Takasaki S; Noura M; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Shiba N; Yamato G; Handa H; Ono Y; Hiramoto N; Ishikawa T; Usuki K; Ishiyama K; Miyawaki S; Itonaga H; Miyazaki Y; Kawamura M; Yamaguchi H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Hayashi Y; Mano H; Miyano S; Kamikubo Y; Ogawa S; Adachi S
Blood Adv; 2018 Nov; 2(21):2879-2889. PubMed ID: 30381403
[TBL] [Abstract][Full Text] [Related]
22. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
Liu W; Deng L; Song Y; Redell M
PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
[TBL] [Abstract][Full Text] [Related]
23. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Stam RW; Den Boer ML; Schneider P; de Boer J; Hagelstein J; Valsecchi MG; de Lorenzo P; Sallan SE; Brady HJ; Armstrong SA; Pieters R
Blood; 2010 Feb; 115(5):1018-25. PubMed ID: 19965632
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
[TBL] [Abstract][Full Text] [Related]
25. The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia.
Balgobind BV; Zwaan CM; Pieters R; Van den Heuvel-Eibrink MM
Leukemia; 2011 Aug; 25(8):1239-48. PubMed ID: 21566656
[TBL] [Abstract][Full Text] [Related]
26. Aberrant TRPM4 expression in MLL-rearranged acute myeloid leukemia and its blockade induces cell cycle arrest via AKT/GLI1/Cyclin D1 pathway.
Wang F; Wu P; Gong S; Chen Y; Gao J; Wang S; Shen Q; Tao H; Hua F; Zhou Z; Zou Z; Ma T; Jia Y
Cell Signal; 2020 Aug; 72():109643. PubMed ID: 32320859
[TBL] [Abstract][Full Text] [Related]
27. FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML.
Sheng Y; Yu C; Liu Y; Hu C; Ma R; Lu X; Ji P; Chen J; Mizukawa B; Huang Y; Licht JD; Qian Z
Nat Commun; 2020 Feb; 11(1):928. PubMed ID: 32066721
[TBL] [Abstract][Full Text] [Related]
28. miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia.
Chen P; Price C; Li Z; Li Y; Cao D; Wiley A; He C; Gurbuxani S; Kunjamma RB; Huang H; Jiang X; Arnovitz S; Xu M; Hong GM; Elkahloun AG; Neilly MB; Wunderlich M; Larson RA; Le Beau MM; Mulloy JC; Liu PP; Rowley JD; Chen J
Proc Natl Acad Sci U S A; 2013 Jul; 110(28):11511-6. PubMed ID: 23798388
[TBL] [Abstract][Full Text] [Related]
29. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.
Arai S; Yoshimi A; Shimabe M; Ichikawa M; Nakagawa M; Imai Y; Goyama S; Kurokawa M
Blood; 2011 Jun; 117(23):6304-14. PubMed ID: 21190993
[TBL] [Abstract][Full Text] [Related]
30. Molecular pathogenesis of disease progression in MLL-rearranged AML.
Kotani S; Yoda A; Kon A; Kataoka K; Ochi Y; Shiozawa Y; Hirsch C; Takeda J; Ueno H; Yoshizato T; Yoshida K; Nakagawa MM; Nannya Y; Kakiuchi N; Yamauchi T; Aoki K; Shiraishi Y; Miyano S; Maeda T; Maciejewski JP; Takaori-Kondo A; Ogawa S; Makishima H
Leukemia; 2019 Mar; 33(3):612-624. PubMed ID: 30209403
[TBL] [Abstract][Full Text] [Related]
31. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
[TBL] [Abstract][Full Text] [Related]
32. Autophagy is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and anti-leukemic effect of chloroquine.
Chen X; Clark J; Wunderlich M; Fan C; Davis A; Chen S; Guan JL; Mulloy JC; Kumar A; Zheng Y
Autophagy; 2017 May; 13(5):955-966. PubMed ID: 28282266
[TBL] [Abstract][Full Text] [Related]
33. C-terminal BRE inhibits cellular proliferation and increases sensitivity to chemotherapeutic drugs of MLL-AF9 acute myeloid leukemia cells.
Pun CC; Lee KK; Chui YL
Leuk Lymphoma; 2019 Dec; 60(12):3011-3019. PubMed ID: 31111759
[TBL] [Abstract][Full Text] [Related]
34. The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.
Lavallée VP; Baccelli I; Krosl J; Wilhelm B; Barabé F; Gendron P; Boucher G; Lemieux S; Marinier A; Meloche S; Hébert J; Sauvageau G
Nat Genet; 2015 Sep; 47(9):1030-7. PubMed ID: 26237430
[TBL] [Abstract][Full Text] [Related]
35.
Fu JF; Shih LY; Yen TH
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34080665
[TBL] [Abstract][Full Text] [Related]
36. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
[TBL] [Abstract][Full Text] [Related]
37. MLL-AF9 leukemia stem cells: hardwired or taking cues from the microenvironment?
Muntean AG; Hess JL
Cancer Cell; 2008 Jun; 13(6):465-7. PubMed ID: 18538728
[TBL] [Abstract][Full Text] [Related]
38. Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements.
Liu J; Qin YZ; Yang S; Wang Y; Chang YJ; Zhao T; Jiang Q; Huang XJ
Ann Hematol; 2017 Apr; 96(4):567-574. PubMed ID: 28054140
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic regulation of protein translation in KMT2A-rearranged AML.
Lenard A; Xie HM; Pastuer T; Shank T; Libbrecht C; Kingsley M; Riedel SS; Yuan ZF; Zhu N; Neff T; Bernt KM
Exp Hematol; 2020 May; 85():57-69. PubMed ID: 32437908
[TBL] [Abstract][Full Text] [Related]
40. Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia.
de Groot AP; Saito Y; Kawakami E; Hashimoto M; Aoki Y; Ono R; Ogahara I; Fujiki S; Kaneko A; Sato K; Kajita H; Watanabe T; Takagi M; Tomizawa D; Koh K; Eguchi M; Ishii E; Ohara O; Shultz LD; Mizutani S; Ishikawa F
EBioMedicine; 2021 Feb; 64():103235. PubMed ID: 33581643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
